A New Vision

for your patients with an

inherited retinal disease (IRD)

LUXTURNA is a one-time gene therapy for patients with an IRD due to biallelic RPE65 gene mutations who have viable retinal cells1

Photographs are not of actual patients.

A novel endpoint was developed to measure how LUXTURNA affects functional vision1

SEE THE RESULTS IN ACTION

Find out if your patients have biallelic RPE65 mutations

Stay informed by registering for updates